Talphera — Third Quarter 2026 Earnings Summary

Talphera reported a net loss of $4.0 million for the third quarter of 2026, with cash and investments totaling $14.2 million as of September 30, 2026. The company submitted a briefing document to the FDA seeking approval to close enrollment in its NEPHRO CRRT study by December 31, 2026, citing that the current enrollment of over 75% of the target provides more than 80% statistical power for the primary endpoint. Updated market research has raised the estimated peak sales for nafamostat in the CRRT market to over $200 million. Talphera plans to file a Form S-3 Shelf Registration Statement to replace its existing registration that expires in November 2026.